Swamped with orders for Molnuparivir after its brand Molnarz obtained last month the emergency use authorization (EUA), Faberco Life Sciences Inc. (FLSI) is gearing up for the rollout of Covovax, a vaccine against the new coronavirus disease 2019 (COVID-19).
Dr. Ma. Luningning Ello Villa, medical director of FLSI, said the company is consolidating orders and will renegotiate with local government units (LGUs) with which it has term sheets for Covavax.
The Food and Drug Administration (FDA) in November approved the EUA of Covavax by Novavax Inc.
Covovax will be manufactured by Serum Institute of India, and is approved for use on adults 18 and above.
The FDA had said Covovax, which had efficacy of 89.7 percent in clinical trials, will be administered in two doses not less than 21 days apart.
Villa said while there has been a delay in the availability of the vaccine to the Philippines, FLSI has received expressions of interest for Covavx.
Villa aded the company is committed to contributing to the government’s aim for consistent availability of the anti-viral drug against COVID-19 and to respond to the health emergency.
Villa said Aurobindo Pharma Ltd., the top branded generic drug manufacturer in India under license by Merck, USA, has a high manufacturing capacity for Molnarz that would enable FLSI to deliver and cater to the needs of more hospitals and other institutions and administer it to COVID-19 patients at a reasonable price.
FLSI has been providing Molnarz to a number of hospitals, local government units and distributors since last year under compassionate special permit. – Irma Isip
